LON:MXCTMaxCyte Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MaxCyte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 206 -6.00 (-2.83 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range 202Now: GBX 206▼ 21650-Day Range 167.50MA: GBX 186.58▼ 21252-Week Range 95Now: GBX 206▼ 212Volume626,640 shsAverage Volume1,951 shsMarket Capitalization£157.77 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines MaxCyte, Inc. operates as a cell-based medicines and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers, as well as transfection insourcing services. In addition, it develops CARMA, a messenger ribonucleic acid autologous platform for immune-oncology that enables manufacture and controllable delivery of next-generation chimeric antigen receptor engineered T/NK-cell therapies for a range of cancer indications, including solid tumors. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. has a cooperative research and development agreement with the National Institutes of Health's and National Institute of Allergy and Infectious Diseases to develop treatments for X-linked chronic granulomatous disease using gene correction leveraging CRISPR/Cas9; and a research agreement with Kite Pharma, Inc. to enable non-viral cell engineering. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland. MaxCyte, Inc. is a subsidiary of CASI Pharmaceuticals, Inc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for MaxCyte. Previous Next 2.6 Community Rank Outperform VotesMaxCyte has received 151 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMaxCyte has received 139 “underperform” votes. (Add your “underperform” vote.)Community SentimentMaxCyte has received 52.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote “Outperform” if you believe MXCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from GBX (0.30) to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:MXCT Previous Symbol CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700Debt Debt-to-Equity Ratio53.02 Current Ratio2.62 Quick Ratio2.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£21.62 million Price / Sales7.30 Cash FlowGBX 28.28 per share Price / Cash Flow7.29 Book ValueGBX 23.70 per share Price / Book8.69Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares76,585,000Market Cap£157.77 million Next Earnings DateN/A OptionableNot Optionable LSE:MXCT Rates by TradingView Receive MXCT News and Ratings via Email Sign-up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. MaxCyte (LON:MXCT) Frequently Asked Questions How has MaxCyte's stock been impacted by COVID-19 (Coronavirus)? MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MXCT stock has increased by 37.3% and is now trading at GBX 206. View which stocks have been most impacted by Coronavirus. Has MaxCyte been receiving favorable news coverage? News coverage about MXCT stock has trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MaxCyte earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about MaxCyte. Who are some of MaxCyte's key competitors? Some companies that are related to MaxCyte include Profound Medical (PRN), Renalytix Ai (RENX), Volpara Health Tech (VHT), Legend Biotech (GTH), Akumin (AKU), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), Palatin Technologies (PTN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR) and BARD1 Life Sciences (BD1). View all competitors. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include Boohoo Group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Artelo Biosciences (ARTL), Arch Therapeutics (ARTH), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Argan (AGX), Applied Genetic Technologies (AGTC) and Allergan (AGN). Who are MaxCyte's key executives? MaxCyte's management team includes the following people: Mr. Douglas Arthur Doerfler, Co-Founder, CEO, Pres & Exec. Director (Age 63)Mr. Ronald Evan Holtz, CFO, Sec. & Director (Age 61)Mr. Maher Masoud, VP of LegalMr. Thomas Michael Ross, Exec. VP of Global Sales (Age 58)Mr. Markus J. Hunkeler, VP of Marketing What is MaxCyte's stock symbol? MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT." How do I buy shares of MaxCyte? Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is MaxCyte's stock price today? One share of MXCT stock can currently be purchased for approximately GBX 206. How big of a company is MaxCyte? MaxCyte has a market capitalization of £157.77 million and generates £21.62 million in revenue each year. What is MaxCyte's official website? The official website for MaxCyte is www.maxcyte.com. How can I contact MaxCyte? MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
